What is it about?
Tezepelumab, an anti-TSLP antibody, reduces inflammation in asthma. In this study, it improved steroid sensitivity in severe asthma, likely by suppressing inflammatory pathways. These findings suggest tezepelumab can restore steroid response for patients who do not respond well to steroids alone.
Featured Image
Photo by CNordic Nordic on Unsplash
Why is it important?
For the first time, these results suggest tezepelumab can restore steroid sensitivity. This leads to better symptom control and outcomes for those with severe asthma who respond poorly to steroids alone.
Perspectives
This study represents a notable advance in the ongoing investigation of the molecular mechanisms underlying steroid resistance in severe asthma. Building on previous findings that benralizumab can restore steroid sensitivity, the current results demonstrate that blocking TSLP with tezepelumab also upregulates key genes, including NR3C1 (glucocorticoid receptor) and HDAC2. These findings validate the hypothesis that biologics not only suppress downstream inflammation but also fundamentally repair cellular dysregulation caused by the PI3K and MAPK pathways. The most significant implication is the potential to achieve clinical remission; by restoring steroid sensitivity, it may be possible to stratify patients more effectively and ensure they receive the biologic therapy that re-enables their response to standard treatments.
Keita Hirai
Shinshu Daigaku
Read the Original
This page is a summary of: Tezepelumab Targeting Thymic Stromal Lymphopoietin Enhances Steroid Sensitivity in Patients With Severe Asthma, Allergy, September 2025, Wiley,
DOI: 10.1111/all.70083.
You can read the full text:
Contributors
The following have contributed to this page
